Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Esophageal Adenocarcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Esophageal Cancer (195)

Esophageal Squamous Cell Carcinoma (90)

Esophageal Cancer (195)

Esophageal Squamous Cell Carcinoma (90)

›

No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
PD-L1 expression	Esophageal Adenocarcinoma	PD-L1 expression	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2	FOLFOX Sensitive: A2 - Guideline FOLFOX Sensitive : A2
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
MSI-H/dMMR	Esophageal Adenocarcinoma	MSI-H/dMMR	Esophageal Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2